1. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer. (15th January 2023) Authors: Huang, Wei-Sheng; Li, Feng; Gong, Yongjin; Zhang, Yun; Youngsaye, Willmen; Xu, Yongjin; Zhu, Xiaotian; Greenfield, Matthew T.; Kohlmann, Anna; Taslimi, Paul M.; Toms, Angela; Zech, Stephan G.; Zhou, Tianjun; Das, Biplab; Jang, Hyun G.; Tugnait, Meera; Ye, Yihua E.; Gonzalvez, Francois; Baker, The... Journal: Bioorganic & medicinal chemistry letters Issue: Volume 80(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗